, a bio/informatics shared resource is still "open for business" - Visit the CDS website

The role of magnetic resonance imaging biomarkers in clinical trials of treatment response in cancer.

Yankeelov TE, Arlinghaus LR, Li X, Gore JC
Semin Oncol. 2011 38 (1): 16-25

PMID: 21362513 · PMCID: PMC3073543 · DOI:10.1053/j.seminoncol.2010.11.007

Current standard-of-care radiological methods for assessing the response of solid tumors to treatment are based on measuring changes in lesion size in a single dimension using high-resolution x-ray computed tomography (CT) or magnetic resonance imaging (MRI). Even if size measurements are adapted to record true volume changes more accurately, the effects of therapeutic drugs on tumor size may not occur for several cycles of treatment. Furthermore, current and future generations of anticancer drugs will be designed to affect highly specific cancer characteristics, and their effects may not be immediately cytotoxic. More sensitive and specific measures are required that can report on tumor status and treatment response early in the course of therapy. Several MRI techniques have matured to the point where they can offer quantitative information on tissue status and greater insight into specific biophysical and physiological characteristics of tumors. Here we review and provide illustrative examples of two MRI methods that have already been incorporated into clinical trials of treatment response in solid tumors: diffusion imaging and dynamic contrast-enhanced MRI. We also discuss the limitations and future research directions required for these techniques to gain greater acceptance and to have their maximum impact.

Copyright © 2011 Elsevier Inc. All rights reserved.

MeSH Terms (9)

Antineoplastic Agents Biomarkers Clinical Trials as Topic Diffusion Magnetic Resonance Imaging Drug Monitoring Humans Magnetic Resonance Imaging Molecular Imaging Neoplasms

Connections (2)

This publication is referenced by other Labnodes entities: